Gilead Sciences (GILD) Declares $0.47 Quarterly Dividend; 2.1% Yield
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Jefferies Remains Sidelined on Gilead Sciences (GILD) Following 2Q - PT to $93
July 26, 2016 9:15 AM EDTJefferies maintained a Hold rating on Gilead Sciences (NASDAQ: GILD), and cut the price target to $93.00 (from $97.00) following the company's 2Q earnings report. GILD's strong bottom-line results were driven by HIVB strength, as well as buybacks. HIV sales remain strong, with particular... More
Gilead Sciences (GILD) Tops Q2 EPS by 6c
July 25, 2016 4:09 PM EDTGilead Sciences (NASDAQ: GILD) reported Q2 EPS of $3.08, $0.06 better than the analyst estimate of $3.02. Revenue for the quarter came in at $7.78 billion versus the consensus estimate of $7.79 billion.
otal product sales for the second quarter of 2016 were $7.7 billion compared to $8.1 billion for the same period in 2015. Product sales for the second quarter of 2016 were $4.9... More
